We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Endra said it will send the FDA additional limited confirmatory clinical data from a subset of its existing clinical evaluation sites, which it expects to receive this year. Read More
Johnson & Johnson subsidiary DePuy Synthes has acquired CrossRoads Extremity Systems, a Memphis, Tenn.-based company that will strengthen DePuy’s portfolio in elective foot and ankle implants and surgical instruments. Read More
Two Canadian companies, Imagia Cybernetics and Canexia Health, are merging to create a new entity that will focus on genomic testing and analysis for cancer patients. Read More
Cambridge, Mass.-based Foundation Medicine has teamed up with Eli Lilly for the development of tissue- and blood-based assays as companion diagnostics for Lilly’s cancer drug Retevmo and other therapies. Read More
The FDA did not believe the company provided enough clinical evidence to support the expanded indication, as the system had not met the primary endpoints of its sebaceous hyperplasia study. Read More